RECRUITING

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.

Official Title

Contrast Ultrasound vs. Abbreviated MRI for Detection of HCC in Patients With Indeterminate Liver Nodules

Quick Facts

Study Start:2023-11-28
Study Completion:2027-11-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06184152

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
  2. * Adults 18 years old and above
  1. * Patients post liver transplantation
  2. * Patients with concurrent or prior HCC (LR-5 or biopsy proven)
  3. * other liver cancer including cholangiocarcinoma
  4. * Patients with any active extra-hepatic malignancy
  5. * Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit
  6. * Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia

Contacts and Locations

Study Contact

Lisa Quirk, MS/MPH
CONTACT
214-645-6179
lisa.quirk@utsouthwestern.edu
Sneha Deodhar, MS
CONTACT
214-645-1378
sneha.deodhar@utsouthwestern.edu

Study Locations (Sites)

University of Michigan
Ann Arbor, Michigan, 48109
United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
United States

Collaborators and Investigators

Sponsor: University of Texas Southwestern Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-28
Study Completion Date2027-11-28

Study Record Updates

Study Start Date2023-11-28
Study Completion Date2027-11-28

Terms related to this study

Keywords Provided by Researchers

  • LR3
  • LR4
  • HCC Surveillance

Additional Relevant MeSH Terms

  • HCC
  • Hepatocellular Carcinoma